Search

Displaying results 6211 - 6220 of 10000 in total
  1. Drug

    Elastin (human)

    go.drugbank.com/drugs/DB15364
    Experimental

    Elastin (human) is under investigation in clinical trial NCT01466413 (Two Formulations of ELAPR Compared to Restylane® Vital Light Following Repeat Implants in the Upper Arm Dermis).

  2. Drug

    TPMPA

    go.drugbank.com/drugs/DB16754
    Experimental

    [A245308,A245313] TPMPA is used as a pharmacological probe for the investigation of GABA<sub>C</sub> receptor function.[A245313] … [A245303] GABA<sub>C</sub> receptors are found primarily in the retina, although they may be present in other tissues, including the hippocampus, spinal cord, superior colliculus, pituitary and the gut

  3. Drug

    Telratolimod

    go.drugbank.com/drugs/DB19590
    Investigational

    The usage of the INN stem '-tolimod' in the name indicates that Telratolimod is a toll-like receptor (TLR) agonist. … Telratolimod is under investigation in clinical trial NCT06680479 (Safety and Immunogenicity of Stabilized CH505 TF chTrimer Vaccination in Adults Living With HIV-1 on Suppressive Antiretroviral Therapy

  4. Drug

    Relutrigine

    go.drugbank.com/drugs/DB21614
    Investigational

    The usage of the INN stem '-trigine' in the name indicates that Relutrigine is a sodium channel blocker, signal transduction modulator. … Relutrigine is under investigation in clinical trial NCT07010471 (A Clinical Trial for Participants With DEE to Assess Efficacy, Safety, Tolerability, and PK of Relutrigine).

  5. Drug

    APL-9

    go.drugbank.com/drugs/DB16460
    Investigational

    APL-9 is an investigational drug intended to centrally control the complement cascade at C3, potentially treating various diseases caused by excessive or uncontrolled complement activation. … It shares the same mechanism of action as Apellis’ lead compound, pegcetacoplan (APL-2), but with a lower molecular weight and shorter half-life.

  6. Drug

    SAR445136

    go.drugbank.com/drugs/DB17708
    Investigational

    [A259063] It was formerly investigated for the treatment of beta-thalassemia, and it is currently being investigated for the treatment of sickle cell disease.[L46148] … It consists of autologous CD34+ hematopoietic stem precursor cells (HSPC) modified ex vivo by zinc finger nucleases (ZFN) that target the BCL11A gene erythroid-specific enhancer (ESE) to increase endogenous

  7. Drug

    MVC-COV1901

    go.drugbank.com/drugs/DB15854
    Investigational

    The vaccine candidate contains a perfusion form of the SARS-Cov2 recombinant spike protein. … As of September 2020, the vaccine candidate is in Phase 1 clinical trials to assess its safety and immunogenicity (NCT04487210).

  8. Drug

    Benidipine

    go.drugbank.com/drugs/DB09231
    Investigational

    Benidipine has the formula 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridine-dicarboxylic acid methyl 1-(phenylmethyl)-3-piperidinyl ester hydrochloride.

  9. Drug

    PSN9301

    go.drugbank.com/drugs/DB05001
    Experimental

    PSN9301 is an oral small molecule inhibitor of Dipeptidyl Peptidase IV (DP-IV), being developed for the treatment of type 2 diabetes. … PSN9301 has a very rapid onset and a relatively short duration of action, and available pre-clinical and clinical data indicate that it may be an ideal product candidate for meal-related dosing.

  10. Drug

    FINLAY-FR-1

    go.drugbank.com/drugs/DB16524
    Experimental

    It is currently being tested in the clinical trial RPCEC00000332 (Phase I / II, randomized, controlled, adaptive, double-blind and multicenter study to evaluate the safety, reactogenicity and immunogenicity … , of the prophylactic FINLAY-FR-1 anti-SARS-CoV-2 Vaccine Candidate in a two-doses schedule.